GenesisCare UK Plans Lunit AI Rollout as Usage and Costs Take Focus
UK cancer care provider GenesisCare UK outlined plans on November 2 to introduce Lunit’s mammography artificial intelligence while retaining review by two radiologists for every mammogram. The software will provide breast density assessments and highlight suspicious lesions, with clinicians making the final decisions. The arrangement illustrates why the business case for Korean medical imaging AI…
GenesisCare UK announced plans on November 2 to integrate Lunit’s AI technology into their mammography screening process. The AI will assist radiologists by providing breast density assessments and highlighting potential suspicious lesions, but human review will still be mandatory for every mammogram. GenesisCare aims to reduce unnecessary callbacks and biopsies through this AI support, which would improve clinical judgment and patient outcomes.
The business case for implementing AI in medical imaging abroad depends on various factors, including the software's usage, operating costs, and patient benefits. In November, GenesisCare confirmed the adoption plan but did not specify the start date, the number of participating sites, or the volume of paid examinations. Lunit had already recognized GenesisCare as a customer on August 3, listing their products as mammography quality and operational management tools, along with Lunit INSIGHT MMG and DBT.
Despite securing the contract, GenesisCare did not disclose the commercial terms, such as pricing models or the expected revenue from the AI deployment. The announcement emphasized that the business case for AI in medical imaging abroad requires evidence of increased usage, reduced costs, and improved patient outcomes to form the basis of a sustainable overseas business model.
Written by urgent.news from Korea IT Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
